Pfizer 2026 AGM: 12 directors reelected, KPMG ratified

What Pfizer announced after its annual meeting

Pfizer Inc. (NYSE: PFE) said it has held its Annual Meeting of Shareholders and released preliminary voting results. The meeting covered board elections, auditor ratification, an amendment to the company’s equity plan, an advisory vote on executive compensation, and a shareholder proposal.

The company said shareholders reelected all 12 director nominees to one-year terms. Shareholders also ratified KPMG LLP as Pfizer’s independent registered public accounting firm for the 2026 fiscal year.

Pfizer added that shareholders approved the Pfizer 2019 Stock Plan, as amended in April 2026. They also approved, on an advisory basis, the compensation of the company’s named executive officers.

Preliminary outcomes and what did not pass

Alongside the items supported by shareholders, Pfizer said shareholders did not approve the shareholder proposal. In the broader meeting agenda described in the filing summary, that shareholder proposal related to adopting an Independent Chair Policy.

Pfizer’s update framed the results as preliminary. The company said the final results are subject to verification by the independent inspectors of election.

When the final vote count will be disclosed

Pfizer said the final results will be reported on a Current Report on Form 8-K. The filing is expected to be submitted with the U.S. Securities and Exchange Commission in the next few days.

This is a standard process following annual meetings in the US, where companies publish certified vote tallies after independent verification.

Meeting format and agenda details from the filing summary

A filing summary referenced Pfizer’s annual meeting scheduled for April 23, 2026, to be held virtually at 9:00 a.m. EDT. It also noted that shareholders could access proxy materials and vote online or request printed copies.

The same summary outlined five key voting matters: election of 12 directors, ratification of KPMG as auditor for 2026, approval of the amended 2019 Stock Plan, an advisory vote on executive pay for 2026, and a shareholder proposal for an independent chair.

Key resolutions: what shareholders voted on

How this fits into Pfizer’s recent financial narrative

While the annual meeting vote is a governance event, the company’s recent reported financial snapshots provide context on the operating backdrop in which shareholders were voting.

The filing summary cited a quarterly revenue figure of $17.7 billion for “Q3 2024,” described as up 31% to 32%, with guidance raised on strong oncology and vaccine growth. It also cited full-year 2025 revenue of $12.6 billion and adjusted EPS of $1.22, alongside commentary pointing to strong non-COVID growth and a 2026 outlook.

Separately, it cited “Q3 2025” revenue of $16.7 billion and adjusted EPS of $1.87, and noted that 2025 EPS guidance was raised to $1.00 to $1.15.

India-listed Pfizer Ltd: board meeting and trading window disclosure

Separate exchange disclosures in the provided text relate to Pfizer Limited (India), including a board meeting outcome and procedural compliance under SEBI regulations.

Pfizer Limited informed BSE and NSE that its Board of Directors met on February 9, 2026, starting at 3:00 p.m. and concluding at 4:45 p.m., to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The company said it also enclosed a Limited Review Report issued by statutory auditors B S R & Co. LLP.

The text also stated that the trading window for company shares was closed from December 31, 2025, and would remain closed until 48 hours after the results are made public.

Some financial line items visible in the excerpt include earnings per share figures (basic and diluted) and other equity, and a note that an exceptional item for the year ended March 31, 2025 related to a net gain of INR 172.81 crore from assignment of lease of MIDC land and sale of a building constructed on such land.

Market impact: what is known from the disclosed facts

The AGM outcomes primarily affect corporate governance and authorization frameworks rather than immediate operating performance. Approval of the amended stock plan keeps the company’s equity incentive framework in place, while the advisory approval of executive pay indicates shareholder support on compensation matters, based on the preliminary count.

On the business side, the only quantified operating indicators in the provided material were revenue and adjusted EPS figures cited in the filing summary. Those figures point to a revenue base of $12.6 billion for 2025 and quarterly revenues of $17.7 billion and $16.7 billion for the periods labeled in the summary, with adjusted EPS of $1.22 for 2025.

For Pfizer Limited in India, the exchange communication was centered on the timing of financial results approval, the limited review process, and the trading window closure, rather than detailed revenue or profit disclosures in the excerpt.

Analysis: why the voting outcomes matter

Director elections, auditor ratification, and stock plan approvals are routine but consequential because they shape oversight, financial reporting credibility, and compensation structures. The preliminary reelection of all 12 directors signals continuity in board composition for the next one-year term.

Ratifying KPMG for the 2026 fiscal year maintains continuity in external audit arrangements. Meanwhile, rejection of the independent chair proposal, as referenced in the filing summary, indicates shareholders did not back a structural change to board leadership through that specific proposal.

What to watch next

Pfizer said it will publish final, inspector-verified voting results in a Form 8-K filing with the SEC in the next few days. Investors tracking governance changes typically monitor the final certified vote totals, including support levels for each proposal.

In India, Pfizer Limited’s disclosures indicate the company has already completed its February 9, 2026 board meeting and approved unaudited results for the quarter and nine months ended December 31, 2025, with the limited review report to be filed with stock exchanges and made available on the company website.